Authors: Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Chen Y; Fujian Cancer Hospital, Fuzhou, China., Luo Z; Fudan University Shanghai Cancer Center, Shanghai, China., Zou Z; Drum Tower Hospital, Affiliated to Medical School of Nanjing University, Nanjing, China., Jiang Y; West China Hospital, Sichuan University, Chengdu, China., Pan H; Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China., Fan Q; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Zhao J; The First Affiliated Hospital of Jinan University, Guangzhou, China., Xu Q; Shanghai Tenth People's Hospital, Shanghai, China., Jiang R; The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, China., Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Ma T; Taizhou Hanzhong Biomedical Co., Ltd. (A Member of Lepu Biopharma Co., Ltd.), Taizhou, China., Guo Z; The First Hospital of Jilin University, Changchun, China., Si L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Chi Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Dou Y; Taizhou Hanzhong Biomedical Co., Ltd. (A Member of Lepu Biopharma Co., Ltd.), Taizhou, China., Tan Q; Taizhou Hanzhong Biomedical Co., Ltd. (A Member of Lepu Biopharma Co., Ltd.), Taizhou, China., Wu D; The First Hospital of Jilin University, Changchun, China. wudi1971@jlu.edu.cn., Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. guoj307@126.com.

Source: BMC cancer [BMC Cancer] 2023 Feb 06; Vol. 23 (1), pp. 121. Date of Electronic Publication: 2023 Feb 06.

Publication Type: Clinical Trial, Phase II; Multicenter Study; Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Authors: Hicks D; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Baehr C; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Silva-Ortiz P; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Khaimraj A; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Luengas D; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Hamid FA; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Pravetoni M; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.; Center for Immunology, University of Minnesota, Minneapolis, MN, USA.; School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.

Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2122507. Date of Electronic Publication: 2022 Oct 04.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Authors: Fan Y; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Sun Z; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Conrad F; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Wen W; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Zhao L; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Lou J; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Zhou Y; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Farr-Jones S; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America., Marks JD; Zuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.

Source: PloS one [PLoS One] 2022 Sep 01; Vol. 17 (9), pp. e0273512. Date of Electronic Publication: 2022 Sep 01 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Authors: Enevold C; Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Loft N; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark., Bregnhøj A; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.; Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark., Zachariae C; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Iversen L; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.; Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark., Skov L; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Nielsen CH; Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Source: JAMA dermatology [JAMA Dermatol] 2022 Jul 01; Vol. 158 (7), pp. 762-769.

Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE

Authors: Moreno V; START Madrid-FJD. Hospital Fundación Jiménez Díaz, Madrid, Spain. victor.moreno@startmadrid.com., Perets R; Rambam Health Care Campus, Technion - Israel Institute of Technology, Haifa, Israel., Peretz-Yablonski T; The Sharett Oncology Institure, Hebrew University-Hadassah Medical Center, Jerusalem, Israel., Fourneau N; Janssen Research & Development, Beerse, Belgium., Girgis S; Janssen Research & Development, LLC, Spring House, PA, USA., Guo Y; Janssen Research & Development, LLC, Spring House, PA, USA., Hellemans P; Janssen Research & Development, Beerse, Belgium., Verona R; Janssen Research & Development, LLC, Spring House, PA, USA., Pendás N; Janssen Research & Development, Madrid, Spain., Xia Q; Janssen Research & Development, LLC, Spring House, PA, USA., Geva R; Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.

Source: Investigational new drugs [Invest New Drugs] 2023 Feb; Vol. 41 (1), pp. 93-104. Date of Electronic Publication: 2022 Dec 20.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/pharmacokinetics , Neoplasms*/drug therapy , Neoplasms*/pathology, Adult ; Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Administration, Intravenous ; Dose-Response Relationship, Drug

Authors: Kang JJ; Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA., Ko A; Department of Surgery, VA Greater Los Angeles Healthcare System/UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Kil SH; Department of Surgery, VA Greater Los Angeles Healthcare System/UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Mallen-St Clair J; Department of Otolaryngology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Shin DS; Department of Medicine, VA Greater Los Angeles Healthcare System/UCLA David Geffen School of Medicine, Los Angeles, CA, USA; Molecular Biology Institute, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA., Wang MB; Department of Surgery, VA Greater Los Angeles Healthcare System/UCLA David Geffen School of Medicine, Los Angeles, CA, USA; Molecular Biology Institute, UCLA, Los Angeles, CA, USA; Department of Head and Neck Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Srivatsan ES; Department of Surgery, VA Greater Los Angeles Healthcare System/UCLA David Geffen School of Medicine, Los Angeles, CA, USA; Molecular Biology Institute, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA. Electronic address: Eri.Srivatsan@va.gov.

Source: Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2023 Jan; Vol. 1878 (1), pp. 188827. Date of Electronic Publication: 2022 Oct 27.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9806362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2561 (Electronic) Linking ISSN: 0304419X NLM ISO Abbreviation: Biochim Biophys Acta Rev Cancer Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized* , Head and Neck Neoplasms*/drug therapy, Humans ; Cetuximab ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; ErbB Receptors ; Receptor Protein-Tyrosine Kinases ; Immunotherapy ; Tumor Microenvironment

Transliterated Title: Efecto beneficioso del cambio a un segundo anticuerpo monoclonal anti-CGRP en pacientes con migraña no respondedores a un primero.

Authors: Fresán-Restituto D; Hospital Universitario de Navarra, Pamplona, España., Lacalle-Fabo E; Hospital Universitario de Navarra, Pamplona, España., Martín-Bujanda M; Hospital Universitario de Navarra, Pamplona, España., Sarobe-Carricas MT; Hospital Universitario de Navarra, Pamplona, España.

Source: Revista de neurologia [Rev Neurol] 2023 Mar 16; Vol. 76 (6), pp. 213-216.

Publication Type: Letter

Journal Info: Publisher: Revista De Neurologia Country of Publication: Spain NLM ID: 7706841 Publication Model: Print Cited Medium: Internet ISSN: 1576-6578 (Electronic) Linking ISSN: 02100010 NLM ISO Abbreviation: Rev Neurol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal* , Migraine Disorders*, Humans ; Antibodies, Monoclonal, Humanized

Authors: Poirier N; OSE Immunotherapeutics, Nantes, France., Baccelli I; OSE Immunotherapeutics, Nantes, France., Belarif L; OSE Immunotherapeutics, Nantes, France., Abès R; OSE Immunotherapeutics, Nantes, France., Teppaz G; OSE Immunotherapeutics, Nantes, France., Mary C; OSE Immunotherapeutics, Nantes, France., Poli S; Poli Consulting, Geneva, Switzerland., Fromond C; OSE Immunotherapeutics, Nantes, France., Girault I; OSE Immunotherapeutics, Nantes, France., Pengam S; OSE Immunotherapeutics, Nantes, France., Soma E; OSE Immunotherapeutics, Nantes, France., De Sa F; OSE Immunotherapeutics, Nantes, France., Conduzorgues JP; OSE Immunotherapeutics, Nantes, France., Braudeau C; CHU Nantes, Laboratoire d'Immunologie, Centre d'Immunomonitorage Nantes Atlantique, Nantes, France.; CHU Nantes, Nantes Université, INSERM, CR2TI UMR 1064, Nantes, France; and., Josien R; CHU Nantes, Laboratoire d'Immunologie, Centre d'Immunomonitorage Nantes Atlantique, Nantes, France.; CHU Nantes, Nantes Université, INSERM, CR2TI UMR 1064, Nantes, France; and., Volckaert B; SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium., Costantini D; OSE Immunotherapeutics, Nantes, France., Corallo F; OSE Immunotherapeutics, Nantes, France.

Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2023 Mar 15; Vol. 210 (6), pp. 753-763.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal*/therapeutic use , Interleukin-7*, Humans ; Healthy Volunteers ; Antibodies, Monoclonal, Humanized/pharmacology ; Double-Blind Method ; Dose-Response Relationship, Drug

Authors: Davidson TM; Division of Oncology, Mayo Clinic, Rochester, MN, USA., Lebreton CL; Centre Léon Bérard, Lyon, France., Hendricksen AEW; Division of Oncology, Mayo Clinic, Rochester, MN, USA., Atkinson HJ; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA., Larson MC; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA., Oberg AL; Division of Computational Biology, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA., Provencher DM; CHUM - Pavillon Notre-Dame, Montréal, QC, Canada., Glaspy JA; Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA., Karlan BY; Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA., Slamon DJ; Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA., Konecny GE; Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA; Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: gkonecny@mednet.ucla.edu., Ray-Coquard IL; Centre Léon Bérard, Lyon, France; Health Services and Performance Research Lab (EA 7425 HESPER), University Claude Bernard Lyon 1, 69008 Lyon, France.

Source: Gynecologic oncology [Gynecol Oncol] 2023 Mar; Vol. 170, pp. 221-228. Date of Electronic Publication: 2023 Jan 27.

Publication Type: Clinical Trial, Phase II; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized* , Ovarian Neoplasms*/drug therapy, Humans ; Female ; Antibodies, Monoclonal/adverse effects

Authors: Martos-Cabrera L; Hospital Universitario de la Princesa, Madrid, Spain., Llamas-Velasco M; Hospital Universitario de la Princesa, Madrid, Spain., Armesto S; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Herrera-Acosta E; Hospital Virgen de la Victoria, Málaga, Spain., Vidal D; Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain., Vilarrasa E; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Rivera-Diaz R; Hospital Universitario 12 de Octubre, Madrid, Spain., de la Cueva P; Hospital Universitario Infanta Leonor, Madrid, Spain., Martorell-Calatayud A; Hospital de Manises, Valencia, Spain., Ballescá F; Hospital Universitario Germans Trias i Pujol, Barcelona, Spain., Belinchón I; Hospital General Universitario de Alicante - ISABIAL, Alicante, Spain., Carretero G; Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain., Rodríguez L; Hospital Universitario Virgen del Rocío, Sevilla, Spain., Romero-Maté A; Hospital de Fuenlabrada, Madrid, Spain., Pujol-Montcusí J; Hospital Universitari 'Joan XXIII', Tarragona, Spain., Salgado-Boquete L; Complejo Hospitalario Universitario, Pontevedra., Sahuquillo-Torralba A; Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitária La Fe, Valencia, Spain., Coto-Segura P; Hospital Vital Alvarez-Buylla de Mieres, Asturias, Spain., Baniandrés O; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Feltes R; Hospital Universitario la Paz, Madrid, Spain., Alsina M; Hospital Clínic i Provincial, Barcelona, Spain., Daudén E; Hospital Universitario de la Princesa, Madrid, Spain.

Source: International journal of dermatology [Int J Dermatol] 2023 Mar; Vol. 62 (3), pp. e146-e149. Date of Electronic Publication: 2022 Jul 22.

Publication Type: Multicenter Study; Letter

Journal Info: Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized* , Psoriasis*, Humans ; Antibodies, Monoclonal ; Severity of Illness Index ; Treatment Outcome ; Double-Blind Method

Authors: Achini-Gutzwiller FR; Laboratory for Paediatric Immunology, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands.; Division of Paediatric Stem Cell Transplantation and Haematology, Children's Research Centre (CRC), University Children's Hospital of Zurich, Zurich, Switzerland., Jol-van der Zijde CM; Laboratory for Paediatric Immunology, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands., Jansen-Hoogendijk AM; Laboratory for Paediatric Immunology, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands., Lankester AC; Department of Paediatrics, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands; and., Bredius RGM; Department of Paediatrics, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands; and., van Tol MJD; Laboratory for Paediatric Immunology, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands., Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands., Schilham MW; Laboratory for Paediatric Immunology, Willem Alexander Children's Hospital, Leiden University Medical Centre, Leiden, the Netherlands.

Source: Therapeutic drug monitoring [Ther Drug Monit] 2023 Feb 01; Vol. 45 (1), pp. 79-86. Date of Electronic Publication: 2022 Sep 23.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-3694 (Electronic) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal* , Graft vs Host Disease*/prevention & control, Humans ; Alemtuzumab ; Antibodies, Monoclonal, Humanized ; Enzyme-Linked Immunosorbent Assay

Authors: McHugh J; Nature Reviews Rheumatology, . nrrheum@nature.com.

Source: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2023 Feb; Vol. 19 (2), pp. 64.

Publication Type: Journal Article; Comment

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101500080 Publication Model: Print Cited Medium: Internet ISSN: 1759-4804 (Electronic) Linking ISSN: 17594790 NLM ISO Abbreviation: Nat Rev Rheumatol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/adverse effects , Lupus Erythematosus, Systemic*/drug therapy, Humans ; Antibodies, Monoclonal/adverse effects

Authors: Bolchini M; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Schiano di Cola F; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Ceccardi G; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Caratozzolo S; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Liberini P; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Rao R; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy., Padovani A; Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy.

Source: European neurology [Eur Neurol] 2023; Vol. 86 (2), pp. 135-139. Date of Electronic Publication: 2022 Dec 20.

Publication Type: News

Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0150760 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9913 (Electronic) Linking ISSN: 00143022 NLM ISO Abbreviation: Eur Neurol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized* , Migraine Disorders*, Humans ; Retrospective Studies ; Antibodies, Monoclonal/adverse effects ; Treatment Outcome

Authors: Bruce IN; Division of Musculoskeletal & Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Golam S; Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Steenkamp J; EVERSANA™, Burlington, ON, L7N 3H8, Canada., Wang P; EVERSANA™, Burlington, ON, L7N 3H8, Canada., Worthington E; EVERSANA™, Burlington, ON, L7N 3H8, Canada., Desta B; BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA., Psachoulia K; Respiratory, Inflammation & Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA., Erhardt W; Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Tummala R; Respiratory, Inflammation & Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

Source: Journal of comparative effectiveness research [J Comp Eff Res] 2023 Jan; Vol. 12 (1), pp. e220192. Date of Electronic Publication: 2022 Dec 14.

Publication Type: Journal Article

Journal Info: Publisher: Future Medicine Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/therapeutic use , Lupus Erythematosus, Systemic*/drug therapy, Adult ; Humans ; Antibodies, Monoclonal ; Treatment Outcome

Authors: Ballew N; GSK, Value Evidence & Outcomes, Collegeville, PA 19426, USA., Mian A; GSK, Global Medical Affairs, Brentford, Middlesex, UK., Levy RA; GSK, Specialty Care, Global Medical Affairs, Collegeville, PA 19426, USA., Bradley M; GSK, Value Evidence & Outcomes, Brentford, Middlesex, UK.

Source: Journal of comparative effectiveness research [J Comp Eff Res] 2023 Jan; Vol. 12 (1), pp. e220106. Date of Electronic Publication: 2022 Dec 14.

Publication Type: Letter

Journal Info: Publisher: Future Medicine Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/therapeutic use , Lupus Erythematosus, Systemic*/drug therapy, Humans ; Adult ; Antibodies, Monoclonal ; Treatment Outcome

Authors: Djebbari F; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Poynton M; Royal Berkshire Hospital, Reading, UK., Sangha G; Milton Keynes Hospital, Milton Keynes, UK., Anderson L; Royal United Hospital Bath, Bath, UK., Maddams R; Poole Hospital, Poole, UK., Eyre TA; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Vallance G; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Basu S; The Royal Wolverhampton NHS Trust, Wolverhampton, UK.; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK.; West Midlands Research Consortium (WMRC), West Midlands, UK., Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 204-207.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

Authors: Stiboy E; School of Public Health, The University of Sydney, Camperdown, Australia., Chan M; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia., Islam MS; National Center for Epidemiology and Population Health, ANU, Canberra, Australia., Saravanos GL; Chidlren's Hospital Westmead Clinical School, The University of Sydney, Camperdown, Australia.; Susan Wakil School of Nursing and Midwifery, The University of Sydney, Camperdown, Australia., Lui K; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Australian and New Zealand Neonatal Network, UNSW, Sydney, Sydney, Australia.; Deaprtment of Newborn, The Royal Hospital for Women, Randwick, Australia., Jaffe A; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Respiratory Department, The Sydney Children's Hospital, Randwick, Australia., Homaira N; UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.; Respiratory Department, The Sydney Children's Hospital, Randwick, Australia.

Source: Pediatric pulmonology [Pediatr Pulmonol] 2023 Apr; Vol. 58 (4), pp. 1210-1220. Date of Electronic Publication: 2023 Feb 14.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8510590 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-0496 (Electronic) Linking ISSN: 10990496 NLM ISO Abbreviation: Pediatr Pulmonol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal*/therapeutic use , Respiratory Syncytial Virus Infections*/prevention & control , Respiratory Syncytial Virus Infections*/drug therapy, Infant ; Infant, Newborn ; Child ; Humans ; Palivizumab/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Infant, Premature ; Australia ; Respiratory Syncytial Viruses ; Antiviral Agents/therapeutic use ; Hospitalization

Authors: Zhang XC; Department of Oncology, Xintai People's Hospital affiliated to Qilu Medical University, Xintai, China., Chang N; Department of Imaging, Jinan Vocational College of Nursing, Jinan, China., Zhang XQ; Department of Thoracic Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.

Source: Chemical biology & drug design [Chem Biol Drug Des] 2023 Apr; Vol. 101 (4), pp. 848-854. Date of Electronic Publication: 2022 Dec 12.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101262549 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1747-0285 (Electronic) Linking ISSN: 17470277 NLM ISO Abbreviation: Chem Biol Drug Des Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal*/pharmacology , Lung Neoplasms*/drug therapy, Humans ; Cetuximab/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Protein Conformation, beta-Strand ; ErbB Receptors/metabolism ; Peptides/chemistry ; Cell Line, Tumor

Authors: Thaçi D; Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Piaserico S; Unit of Dermatology, Department of Medicine, University of Padova, Padova, Italy., Gaarn Du Jardin K; Almirall R&D, Barcelona, Spain., Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.

Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Apr; Vol. 37 (4), pp. e501-e504. Date of Electronic Publication: 2022 Dec 01.

Publication Type: Clinical Trial, Phase III; Letter

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/therapeutic use , Psoriasis*, Humans ; Antibodies, Monoclonal ; Treatment Outcome ; Severity of Illness Index

Authors: Sigurgeirsson B; Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavík, Iceland., Browning J; Department of Dermatology, University of Texas Health Science Center San Antonio, Texas, USA., Tyring S; Center for Clinical Studies, Houston, Texas, USA., Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland., Rivera-Díaz R; Hospital Universitario 12 de Octubre, Madrid, Spain., Effendy I; Departrment of Dermatology and Allergology, University Hospital of Bielefeld, Bielefeld, Germany., Keefe D; Immunology, Hepatology and Dermatology (IH&D), Novartis Pharmaceuticals Corporation, New Jersey, USA., Bruin G; Immunology, Hepatology and Dermatology (IH&D), Novartis Institutes for Biomedical Research, Basel, Switzerland., Paguet B; Immunology, Hepatology and Dermatology (IH&D), Novartis Pharma AG, Basel, Switzerland., Fu R; Analytics, Immunology, Hepatology and Dermatology (IH&D), Novartis Institutes of for Biomedical Research, Shanghai, China., Hampele I; Immunology, Hepatology and Dermatology (IH&D), Novartis Pharma AG, Basel, Switzerland., Reinhardt M; Immunology, Hepatology and Dermatology (IH&D), Novartis Pharma AG, Basel, Switzerland., Patekar M; Immunology, Hepatology and Dermatology (IH&D), Novartis Pharma AG, Basel, Switzerland.

Source: Dermatologic therapy [Dermatol Ther] 2022 Mar; Vol. 35 (3), pp. e15285. Date of Electronic Publication: 2022 Jan 08.

Publication Type: Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-8019 (Electronic) Linking ISSN: 13960296 NLM ISO Abbreviation: Dermatol Ther Subsets: MEDLINE